Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.83 EUR Market Closed
Market Cap: 132.4m EUR

Wall Street
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 4.59 EUR with a low forecast of 4.55 EUR and a high forecast of 4.73 EUR.

Lowest
Price Target
4.55 EUR
61% Upside
Average
Price Target
4.59 EUR
62% Upside
Highest
Price Target
4.73 EUR
67% Upside
Heidelberg Pharma AG Competitors:
Price Targets
JSPR
Jasper Therapeutics Inc
665% Upside
ARX
Aroa Biosurgery Ltd
31% Upside
ACHV
Achieve Life Sciences Inc
251% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
34% Upside
RXRX
Recursion Pharmaceuticals Inc
37% Upside
BBIO
BridgeBio Pharma Inc
16% Upside
BIOCON
Biocon Ltd
11% Upside
603087
Gan & Lee Pharmaceuticals
3% Upside

Revenue
Forecast

Revenue Estimate
Heidelberg Pharma AG

For the last 8 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 22%. The projected CAGR for the next 3 years is 25%.

22%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-30%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HPHA's stock price target?
Price Target
4.59 EUR

According to Wall Street analysts, the average 1-year price target for HPHA is 4.59 EUR with a low forecast of 4.55 EUR and a high forecast of 4.73 EUR.

What is Heidelberg Pharma AG's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 22%. The projected CAGR for the next 3 years is 25%.

Back to Top